Arbutus Biopharma Corp
$ 4.72
0.85%
17 Apr - close price
- Market Cap 921,678,000 USD
- Current Price $ 4.72
- High / Low $ 4.75 / 4.60
- Stock P/E N/A
- Book Value 0.40
- EPS -0.17
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.38 %
- 52 Week High 5.10
- 52 Week Low 2.94
About
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Analyst Target Price
$5.22
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-13 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.0137 | -0.04 | 0.01 | -0.1816 | -0.0999 | -0.09 | -0.11 | -0.1 | -0.12 | -0.12 | -0.1 | -0.1 |
| Estimated EPS | -0.03 | -0.03 | -0.04 | -0.1538 | -0.1168 | -0.09 | -0.1 | -0.11 | -0.12 | -0.11 | -0.11 | -0.14 |
| Surprise | 0.0163 | -0.01 | 0.05 | -0.0278 | 0.0169 | 0 | -0.01 | 0.01 | 0 | -0.01 | 0.01 | 0.04 |
| Surprise Percentage | 54.3333% | -33.3333% | 125% | -18.0754% | 14.4692% | 0% | -10% | 9.0909% | 0% | -9.0909% | 9.0909% | 28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABUS
2026-04-15 16:10:16
Arbutus Biopharma (NASDAQ:ABUS) experienced unusually strong trading volume on Wednesday, with shares last trading up about 5.2% at $4.486. Despite beating quarterly estimates for EPS and revenue, the company remains unprofitable with a negative net margin and ROE, though it continues to advance its HBV pipeline. Analysts currently maintain an average "Hold" rating for ABUS with a target price of $5.00, while institutional investors have adjusted their holdings in the biopharmaceutical company.
2026-04-15 15:09:33
Arbutus Biopharma Corp (ABUS) has received Fast Track designation from the FDA for its investigational drug imdusiran, intended for chronic hepatitis B. This designation aims to accelerate the development and review process for drugs addressing unmet medical needs. While the company demonstrates strong financial health, its profitability remains a challenge.
2026-04-15 12:08:51
Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for imdusiran, a drug for chronic hepatitis B. This designation will facilitate the development and expedited review of imdusiran, which has shown potential to achieve functional cure in trials. The company plans to work closely with the FDA to advance the drug, addressing a significant unmet medical need for the over 250 million people affected by chronic HBV worldwide.
2026-04-15 11:09:33
Arbutus Biopharma Corp (ABUS) has reported a material event in an 8-K filing, announcing that the FDA granted Fast Track designation for imdusiran, their treatment for chronic hepatitis B. This designation aims to facilitate development and expedite the review process for investigational therapies addressing serious conditions with unmet medical needs. The company highlighted imdusiran's potential, having achieved functional cure in 10 patients to date through clinical trials.
2026-04-14 23:39:10
Whitefort Capital and its related entities have reported an 8.1% beneficial ownership in Arbutus Biopharma (ABUS), acquiring 15,794,261 common shares for approximately $41.8 million. This information was disclosed in an amended form Schedule 13D. The filing provides details on the source of funds, ownership structure, and an exhibit listing all transactions over the past 60 days.
2026-04-14 21:39:33
Arbutus Biopharma is holding its 2026 Annual General and Special Meeting on May 26, 2026, where shareholders will vote on key proposals including the election of five directors, a new 2026 Omnibus Share and Incentive Plan authorizing 16.3 million common shares, an advisory vote on executive compensation, and the appointment of EY as their independent public accounting firm. The new incentive plan aims to attract and retain talent and will replace prior plans, with existing awards continuing under their original terms. The company had 196,939,679 common shares outstanding as of March 30, 2026.
